Vaccines and Immunotherapeutics program

As a key contributor to disease prevention and treatment, vaccines offer low-cost and low-risk options that increase quality of life and reduce health care costs. In partnership with industry, the Vaccines and Immunotherapeutics program develops novel and improved vaccines that prevent viral and bacterial infections and that treat cancer and other chronic diseases.

The Vaccines and Immunotherapeutics program deploys its expertise in immunomodulation, analytics and bioprocessing to enable the Canadian vaccine industry to harness advances in adjuvants, biomarkers and vaccine production. The program's orientation reflects the priorities of industry, which include a strong focus on vaccines that address the needs of adults and the aging population, such as those for cancer and emerging infections.


Collaborate with us

We establish our vaccine development priorities in consultation with the Canadian vaccine industry, as well as by liaising with the Public Health Agency of Canada about national vaccine priorities identified for short, medium, and long term development.


If you're interested in exploring robust and cost‑effective vaccine production methods, developing more effective approaches to immune monitoring and biomarkers, or connecting with our experts, contact:

Lakshmi Krishnan, Program Leader
Telephone: 613- 991-3210

Online request form

Submit an online request for information about our programs and services.

Supplemental content

Targeted industries

Vaccine developers, vaccine manufacturers, biopharmas, biotechs, biomanufacturers, contract research organizations.


"NRC understands what we are trying to do and demonstrated remarkable agility in adapting to our needs."
Adam Buckley, Vice-president of Business Development at VBI Vaccines.
Date modified: